U.S. markets close in 2 hours 4 minutes

Rigel Pharmaceuticals, Inc. (RIGL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.1900+0.0100 (+0.85%)
As of 01:56PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close1.1800
Bid1.1800 x 1100
Ask1.1900 x 4000
Day's Range1.1750 - 1.2500
52 Week Range0.6400 - 3.6200
Avg. Volume3,860,242
Market Cap205.675M
Beta (5Y Monthly)1.54
PE Ratio (TTM)N/A
EPS (TTM)-0.4970
Earnings DateOct 31, 2022 - Nov 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.92
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for RIGL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Rigel Pharmaceuticals, Inc.
    Analyst Report: Lilly(Eli) & CoEli Lilly, based in Indianapolis, develops and manufactures therapies to treat pain, diabetes, cancer, and neurodegenerative diseases. The shares are a component of the S&P 500.
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Simply Wall St.

    Calculating The Fair Value Of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

    Does the September share price for Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) reflect what it's really worth? Today...

  • GlobeNewswire

    Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

    STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company’s financial operations. “Ryan’s deep financial leadership experience will be instrument

  • PR Newswire

    Rigel to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference at 2:00 p.m. ET on Tuesday, September 13, 2022, in New York, NY.